Clinical trials: Headache Migraine Chronic
Intractable Chronic Migraine
Peripheral Nerve Stimulation Registry for Intractable Migraine Headache
The purpose of this study is to evaluate the long-term safety and performance of neurostimulation for the treatment of intractable chronic migraine as well as to detect infrequent complications or problems only apparent in…
- Trial name
- Relief (NCT02227758)
- Where
- 18 sites in Belgium, Germany and 4 more
- Volunteers
- 112 people
- Sponsor
- Abbott Medical Devices
Migraine
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
- Trial name
- DRAGON (NCT03867201)
- Testing
- Erenumab
- Where
- 63 sites in China, India and 7 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Migraine, Healthy
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects.
- Trial name
- NCT01970943
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Migraine Headache
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)
This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and…
- Trial name
- NCT03557333
- Testing
- INP104
- Where
- 36 sites in United States
- Volunteers
- 360 people
- Sponsor
- Impel Pharmaceuticals
Pain
A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
The purpose of this study is to see if changing from one pain medication like morphine or oxycodone to another pain medication, oxymorphone (OPANA®), will be helpful to patients.
- Trial name
- NCT00580294
- Testing
- Oxymorphone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Migraine Disorders, Chronic Disease
"Follow the Sutures". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine
There is no doubt that chronic migraine is a large public health problem, which is both disabling and costly. Many patients and headache doctors see Botulinum toxin (Botox) treatment as a big stride forward, but it is a problem…
- Trial name
- NCT03543254
- Testing
- BoNT-A
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Norwegian University of Science and Technology
Chronic Migraine
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
- Trial name
- REGAIN (NCT02614261)
- Testing
- Galcanezumab
- Where
- 117 sites in United States, Argentina and 11 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Migraine
Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine
The efficacy of intranasal kinetic oscillation stimulation using the Chordate System S211 as a preventative treatment will be examined in patients diagnosed with chronic migraine.
- Trial name
- NCT03400059
- Testing
- Chordate System S211 in treatment mode
- Where
- 10 sites in Finland, Germany
- Volunteers
- 144 people
- Sponsor
- Chordate Medical
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Chronic Migraine, Olfactory Acuity
Smell Sensitivity in Chronic Migraine: A Case-Control Study
Olfactory impairment is a common symptom of neurologic disorders and may be related to dopaminergic dysfunction. Studies show that patients with migraine show increased sensitivity to light and sound.
- Trial name
- NCT01687088
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Chronic Migraine
Efficacy and Safety of Nerivio Device for Acute Treatment of Migraine in People With Chronic Migraine
A prospective, single arm, open-label, multicenter trial to assess the efficacy and safety of the Nerivio device in chronic migraine patients.
- Trial name
- NCT04194008
- Testing
- Nerivio
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- Theranica
Chronic Migraine
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- NCT04829747
- Testing
- Atogepant
- Where
- 3 sites in China
- Volunteers
- 3 people
- Sponsor
- Allergan
Chronic Pain, Migraine
Evaluation of a Mind-body Based Application for the Treatment of Chronic/Persistent Pain.
We are investigating the effects of a mind-body based mobile application on the experience of chronic pain. Participants meeting our criteria for chronic pain (confirmed via self-report) will complete an online baseline…
- Conditions
- Chronic Pain, Migraine, Chronic Pain Syndrome
- Trial name
- NCT05090683
- Testing
- Mind-body mobile application
- Where
- Canada
- Volunteers
- 198 people
- Sponsor
- University of the Fraser Valley
Chronic Migraine
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
- Trial name
- NCT01833130
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Allergan
Migraine
Treatment for Migraines With an Implantable Device
The purpose of this study is to evaluate the safety and effectiveness of an implantable device for difficult to treat migraine. There are a significant number of patients who have drug refractory migraine and alternative…
- Trial name
- NCT00286078
- Testing
- Precision
- Where
- 15 sites in United States
- Volunteers
- 179 people
- Sponsor
- Boston Scientific Corporation
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Migraine
Biomarker and Genetic Predictors of Erenumab Treatment Response
To explore the relationship between clinical response to erenumab and genetic biomarkers
- Trial name
- INTERROGATE (NCT04265755)
- Testing
- Erenumab
- Where
- 2 sites in Denmark, Iceland
- Volunteers
- 1,406 people
- Sponsor
- Amgen
Migraine
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.
- Trial name
- NCT04825678
- Testing
- Erenumab
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Amgen